Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 14/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3094967 | 0.79 | RET (0.37) | IRAK4RETOPRM1 | |
| SCHEMBL3081865 | 0.78 | HRH4 (0.37) | IRAK4PTGDR2PTGDRRET | |
| SCHEMBL4153902 | 0.77 | SCN10A (0.38) | RETOPRM1 | |
| SCHEMBL27632867 | 0.76 | GSK3B (0.37) | RETPARP15PARP10 | |
| SCHEMBL3094958 | 0.69 | HRH4 (0.39) | IRAK4PTGDR2PTGDRRET | |
| SCHEMBL19691288 | 0.68 | HRH4 (0.36) | OPRM1 | |
| SCHEMBL4153906 | 0.66 | SCN10A (0.40) | PTGDR2 | |
| SCHEMBL11679824 | 0.66 | CYP19A1 (0.35) | RET | |
| SCHEMBL28002669 | 0.66 | SCN10A (0.41) | RET | |
| SCHEMBL4414124 | 0.65 | PARP1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173888-A1 | Nicotinamide Derivatives | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173888-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | IRAK4 1251/4885PTGDR2 1729/4885PTGDR 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.